世衛組織暫停了羥氯喹的研究

The World Health Organization is pausing the use of hydroxychloroquine in its global study of COVID-19 treatments amid a review of safety data, officials announced Monday.
週一，世界衛生組織官員宣佈，審查安全數據期間，在對新冠病毒療法的全球研究中暫停使用羥氯喹。
The move follows findings from a large observational study, published Friday, that found increased risk of heart problems and death in COVID-19 patients who used chloroquine and hydroxychloroquine.
此前，在週五發表的一項大型觀察性研究中發現，使用氯喹和羥氯喹的新冠病人患心臟病和死亡的風險會增加，因此做出這一決定。
It’s a scientific decision nonetheless fraught with politics: U.S. President Donald Trump is a champion of hydroxychloroquine, revealing last week that he’s taking it to prevent COVID-19. He has threatened to cut off U.S. funding to the WHO within a month absent unspecified reforms.
儘管如此，但這一科學決定充滿政治因素：美國總統唐納德·特朗普支持羥氯喹，他上週說正在吃羥氯喹來預防感染新冠病毒。他威脅說，如果不進行具體改革，將在一個月內切斷美國對世界衛生組織的資金支持。
The executive committee of the WHO’s Solidarity trial met last Saturday, said WHO Chief Scientist Soumya Swaminathan, and decided “in the light of this uncertainty that we should be proactive, err on the side of caution and suspend enrollment temporarily into the hydroxychloroquine arm.” (Chloroquine is not part of the trial.)
世界衛生組織首席科學家Soumya Swaminathan說，世界衛生組織的SOLIDARITY臨牀試驗執行委員會上週召開會議，決定“鑑於這種不確定性，我們要有前瞻性，謹慎行事，暫停使用羥氯喹”。（氯喹並不是此次試驗用藥。）
The meeting came a day after the Lancet published the largest observational study of the malaria drugs to date, and as some national regulators began expressing concern about using the drug.
會議召開前一天，《柳葉刀》發表了迄今針對瘧疾藥物最大的觀察性研究，一些國家監管機構開始表現出對使用這種藥物的擔憂。
WHO officials estimated the pause would last a week or two as the trial’s data safety monitoring board considers information already collected from the Solidarity trial and other ongoing studies to determine whether it’s safe to continue with hydroxychloroquine.
世界衛生組織官員估計暫停會持續一至兩週，因爲試驗數據安全監測委員會要參考從SOLIDARITY臨牀試驗和其他進行中的研究中所收集的信息，從而確定繼續使用羥氯喹是否安全。
The study, a randomized trial, has enrolled 3,500 patients in at least 17 countries since March to study four medicines, including hydroxychloroquine.
這項研究是隨機試驗，從三月份開始在至少17個國家召集了3,500名患者來研究4種藥物，其中就包括羥氯喹。